Horizon Therapeutics ( ) - 株価, ニュースと分析Nasdaq:HZNP

HZNP 株式概要

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. 詳細

HZNP ファンダメンタル分析
スノーフレーク・スコア
評価	3/6
将来の成長	3/6
過去の実績	1/6
財務の健全性	6/6
配当金	0/6

報酬

当社が推定した公正価値より52.1%で取引されている

収益は年間16.43%増加すると予測されています

リスク分析

財務結果に影響を与える大きな一時的項目

利益率(12%)は昨年より低い(20.1%)

Horizon Therapeutics Public Limited Company 競合他社

United Therapeutics

NasdaqGS:UTHR

US$16.3b

Neurocrine Biosciences

NasdaqGS:NBIX

US$12.5b

Biogen

NasdaqGS:BIIB

US$22.7b

Sarepta Therapeutics

NasdaqGS:SRPT

US$10.6b

価格と性能

の歴代最高値、変動、値下がりまとめHorizon Therapeutics
過去の株価
現在の株価	US$116.30
52週高値	US$116.38
52週安値	US$60.03
ベータ	1.01
11ヶ月の変化	0.76%
3ヶ月変化	12.37%
1年変化	82.80%
33年間の変化	45.18%
5年間の変化	505.10%
IPOからの変化	1,171.04%

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

株主還元

	HZNP	US Biotechs	US 市場
7D	0.06%	-6.5%	-1.0%
1Y	82.8%	14.6%	30.3%

業界別リターン: HZNP過去 1 年間で14.6 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: HZNP過去 1 年間で30.3 % の収益を上げたUS市場を上回りました。

価格変動

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement	2.0%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

安定した株価: HZNP過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: HZNPの週次ボラティリティ ( 2% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2005	2,190	Tim Walbert	www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company 基礎のまとめ

Horizon Therapeutics の収益と売上を時価総額と比較するとどうか。
HZNP 基礎統計学
時価総額	US$26.63b
収益（TTM）	US$438.00m
売上高(TTM)	US$3.64b

60.8x

PER（株価収益率

7.3x

P/Sレシオ

HZNP は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
HZNP 損益計算書（TTM）
収益	US$3.64b
売上原価	US$824.98m
売上総利益	US$2.82b
その他の費用	US$2.38b
収益	US$438.00m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	1.91
グロス・マージン	77.36%
純利益率	12.02%
有利子負債／自己資本比率	48.2%

HZNP の長期的なパフォーマンスは？

過去の実績と比較を見る

HZNP 株式概要

報酬

リスク分析

Horizon Therapeutics Public Limited Company 競合他社

NasdaqGS:UTHR

US$16.3b

NasdaqGS:NBIX

US$12.5b

NasdaqGS:BIIB

US$22.7b

NasdaqGS:SRPT

US$10.6b

価格と性能

最新ニュース

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Insufficient new directors

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Executive VP & Chief Strategy Officer exercised options and sold US$348k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Horizon Therapeutics announces $500M buyback program

Horizon Therapeutics to expand footprint in Ireland

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Consensus revenue estimates fall by 10%

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Price target decreased to US$114

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)